$ENVB
Enveric Biosciences, Inc. Stock $envb

$envb Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222032131 Filed on November 14, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.822M	$3.515M	$2.124M
YoY Change	-70.71%	65.48%	-13.31%
% of Gross Profit
Research & Development	$1.893M	$2.056M	$1.219M
YoY Change	-24.05%	68.59%	1932.23%
% of Gross Profit
Depreciation & Amortization	$86.50K	$44.46K	$484.4K
YoY Change	-49.79%	-90.82%	-13.51%
% of Gross Profit
Operating Expenses	$4.802M	$2.056M	$3.517M
YoY Change	-60.96%	-41.55%	17.23%
Operating Profit		-$5.657M	-$3.517M
YoY Change		60.85%	216.84%
Interest Expense	$1.622M	$308.00	-$370.00
YoY Change	-31717.15%	-183.24%	-100.28%
% of Operating Profit
Other Income/Expense, Net	$469.7K	$3.178M	$804.8K
YoY Change	-67.0%	294.86%
Pretax Income	-$10.16M	-$2.479M	-$2.712M
YoY Change	-79.49%	-8.61%	173.98%
Income Tax	-$1.486M
% Of Pretax Income
Net Earnings	-$8.802M	-$2.479M	-$2.712M
YoY Change	-79.1%	-8.61%	182.54%
Net Earnings / Revenue
Basic Earnings Per Share		-$1.46	-$5.91
Diluted Earnings Per Share	-$4.22	-$1.387M	-$5.860M
COMMON SHARES
Basic Shares Outstanding	2.078M shares	1.575M shares	459.3K shares
Diluted Shares Outstanding		1.787M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.72M	$21.20M	$21.45M
YoY Change	2.12%	-1.15%	655.23%
Cash & Equivalents	$17.72M	$21.20M	$21.45M
Short-Term Investments
Other Short-Term Assets	$708.1K	$1.066M	$833.1K
YoY Change	85.92%	27.93%	-7.43%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$18.43M	$22.27M	$22.28M
YoY Change	3.92%	-0.07%	97.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$677.5K	$712.9K	$140.6K
YoY Change	130.1%	407.18%	-85.51%
Goodwill		$1.468M
YoY Change
Intangibles	$379.7K	$6.319M
YoY Change	-94.52%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.121M	$8.589M	$47.48M
YoY Change	-87.52%	-81.91%	184.63%
TOTAL ASSETS
Total Short-Term Assets	$18.43M	$22.27M	$22.28M
Total Long-Term Assets	$1.121M	$8.589M	$47.48M
Total Assets	$19.55M	$30.86M	$69.76M
YoY Change	-26.82%	-55.77%	149.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$463.3K	$710.3K	$2.163M
YoY Change	-32.21%	-67.16%	-52.78%
Accrued Expenses	$1.706M	$1.113M
YoY Change	31.94%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$3.996M	$2.598M	$2.163M
YoY Change	91.79%	20.13%	-84.54%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$0.00	$2.514M	$3.166M
YoY Change	-100.0%	-20.59%	365.61%
Total Long-Term Liabilities		$4.655M	$3.166M
YoY Change		47.04%	281.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.996M	$2.598M	$2.163M
Total Long-Term Liabilities		$4.655M	$3.166M
Total Liabilities	$3.996M	$7.254M	$14.39M
YoY Change	-9.45%	-49.6%	-2.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$79.21M	-$70.53M
YoY Change	30.41%
Common Stock	$20.78K	$20.78K
YoY Change	218.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$14.67M	$22.84M	$55.37M
YoY Change
Total Liabilities & Shareholders Equity	$19.55M	$30.86M	$69.76M
YoY Change	-26.82%	-55.77%	149.22%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$8.802M	-$2.479M	-$2.712M
YoY Change	-79.1%	-8.61%	182.54%
Depreciation, Depletion And Amortization	$86.50K	$44.46K	$484.4K
YoY Change	-49.79%	-90.82%	-13.51%
Cash From Operating Activities	-$3.462M	-$4.550M	-$2.206M
YoY Change	-14.88%	106.26%	120.62%
INVESTING ACTIVITIES
Capital Expenditures	$6.200K	-$18.57K
YoY Change	-100.72%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$3.055M
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	-$6.200K	-$18.57K	$3.055M
YoY Change	-96.73%	-100.61%	-30653.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$10.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	7.824M	-10.00
YoY Change	-100.0%	-78242300.0%	-100.0%
NET CHANGE
Cash From Operating Activities	-3.462M	-4.550M	-2.206M
Cash From Investing Activities	-6.200K	-18.57K	3.055M
Cash From Financing Activities	0.000	7.824M	-10.00
Net Change In Cash	-3.468M	3.255M	849.1K
YoY Change	-18.53%	283.36%	14.75%
FREE CASH FLOW
Cash From Operating Activities	-$3.462M	-$4.550M	-$2.206M
Capital Expenditures	$6.200K	-$18.57K
Free Cash Flow	-$3.468M	-$4.532M
YoY Change	8.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000890821
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount		usd
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests		usd
CY2022Q3	ENVB	Inducement Expense InducementExpense		usd
CY2021Q3	ENVB	Inducement Expense InducementExpense		usd
CY2021Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
CY2021Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2021Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2021Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment		usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment		usd
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2022Q2	ENVB	Redeemable Noncontrolling Interest Embedded Derivative And Net Of Issuance Costs RedeemableNoncontrollingInterestEmbeddedDerivativeAndNetOfIssuanceCosts		usd
CY2022Q2	ENVB	Accretion Of Embedded Derivative To Redemption Shares AccretionOfEmbeddedDerivativeToRedemptionShares		shares
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2022Q3	ENVB	Issuance Of Rounded Shares As Result Of Reverse Stock Split IssuanceOfRoundedSharesAsResultOfReverseStockSplit		usd
CY2022Q3	ENVB	Accretion Of Embedded Derivative To Redemption Shares AccretionOfEmbeddedDerivativeToRedemptionShares		shares
	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	ENVB	Inducement Expense InducementExpense		usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense		usd
	ENVB	Increase Decrease In Right Of Use Lease Liability IncreaseDecreaseInRightOfUseLeaseLiability		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	ENVB	Proceeds From Amalgamation Agreement ProceedsFromAmalgamationAgreement		usd
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	ENVB	Investment Options Issued In Conjunction With Common Stock Issuance InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance		usd
	ENVB	Modification Of Warrants As Part Of Share Capital Raise ModificationOfWarrantsAsPartOfShareCapitalRaise		usd
	ENVB	Warrants Issued In Conjunction With Notes Payable WarrantsIssuedInConjunctionWithNotesPayable		usd
	ENVB	Issuance Of Embedded Derivative IssuanceOfEmbeddedDerivative		usd
	ENVB	Preferred Dividends Attributable To Redeemable Noncontrolling Interest PreferredDividendsAttributableToRedeemableNoncontrollingInterest		usd
	ENVB	Accretion Of Embedded Derivative To Redemption Value AccretionOfEmbeddedDerivativeToRedemptionValue		usd
	ENVB	Issuance Of Common Stock Pursuant To Amalgamation IssuanceOfCommonStockPursuantToAmalgamation		usd
	ENVB	Deferred Tax Liability Incurred Due To Amalgamation DeferredTaxLiabilityIncurredDueToAmalgamation		usd
	ENVB	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock		usd
	ENVB	Fair Value Of Warrants Issued FairValueOfWarrantsIssued		usd
	ENVB	Fair Value Of Warrants FairValueOfWarrants		usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38286
	dei	Entity Registrant Name EntityRegistrantName	ENVERIC BIOSCIENCES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-4484725
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4851 Tamiami Trail N
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
	dei	Entity Address City Or Town EntityAddressCityOrTown	Naples
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	34103
	dei	City Area Code CityAreaCode	(239)
	dei	Local Phone Number LocalPhoneNumber	302-1707
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
	dei	Trading Symbol TradingSymbol	ENVB
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	2078271	shares
CY2022Q3	us-gaap	Cash Cash	21201005	usd
CY2021Q4	us-gaap	Cash Cash	17355999	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1065795	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	380838	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	22266800	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	17736837	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	712944	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	294430	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	88768	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	176304	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6318509	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	6923928	usd
CY2022Q3	us-gaap	Goodwill Goodwill	1468389	usd
CY2021Q4	us-gaap	Goodwill Goodwill	1587634	usd
CY2022Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	8588610	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	8982296	usd
CY2022Q3	us-gaap	Assets Assets	30855410	usd
CY2021Q4	us-gaap	Assets Assets	26719133	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	710314	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	683393	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1113145	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1292721	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	88769	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	107442	usd
CY2022Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	686000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2598228	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2083556	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	68861	usd
CY2022Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1486413	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1607122	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2514112	usd
CY2022Q3	ENVB	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	654937	usd
CY2021Q4	ENVB	Warrant Liabilities Noncurrent WarrantLiabilitiesNoncurrent	653674	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4655462	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2329657	usd
CY2022Q3	us-gaap	Liabilities Liabilities	7253690	usd
CY2021Q4	us-gaap	Liabilities Liabilities	4413213	usd
CY2022Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	761434	usd
CY2022Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	761434	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2078271	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2078271	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	651921	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	651921	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	20782	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6519	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	93989885	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	83066656	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70529884	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-60736453	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-640497	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-30802	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	22840286	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	22305920	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30855410	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	26719133	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3514547	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2123834	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8783619	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10864696	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2055656	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1219339	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6134421	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2295826	usd
CY2022Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	86646	usd
CY2021Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	173696	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	241413	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	484355	usd
CY2022Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	5656849	usd
CY2021Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	3516869	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	15159453	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	13644877	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5656849	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3516869	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15159453	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13644877	usd
	ENVB	Inducement Expense InducementExpense	298714	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1599623	usd
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-804833	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3845514	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7077376	usd
CY2022Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	1809622	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	1809622	usd
CY2022Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-231000	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-284000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	308	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	370	usd
	us-gaap	Interest Expense InterestExpense	5114	usd
	us-gaap	Interest Expense InterestExpense	5191	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3177937	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	804463	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5366022	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6773471	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2478912	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2712406	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9793431	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6871406	usd
CY2022Q3	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	12603	usd
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	20411	usd
CY2022Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	110991	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	184985	usd
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2602506	usd
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2712406	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9998827	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6871406	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-417390	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-6510	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-609695	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-4036	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3019896	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2718916	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10608522	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6875442	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.46
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.91
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-16.64
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1787235	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	459289	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1232936	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	413063	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	3415641	usd
CY2021Q1	ENVB	Stock Issued During Period Value Issued Direct Offering Net StockIssuedDuringPeriodValueIssuedDirectOfferingNet	4617087	usd
CY2021Q1	ENVB	Stock Issued During Period Value Issued Direct Offering Net One StockIssuedDuringPeriodValueIssuedDirectOfferingNetOne	7016401	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3591565	usd
CY2021Q1	us-gaap	Adjustment To Additional Paid In Capital Convertible Debt Instrument Issued At Substantial Premium AdjustmentToAdditionalPaidInCapitalConvertibleDebtInstrumentIssuedAtSubstantialPremium	298714	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3250711	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	18991678	usd
CY2021Q1	ENVB	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	3267245	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	35736	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	750933	usd
CY2021Q2	ENVB	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	17928	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-33262	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-908289	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	18818988	usd
CY2021Q3	ENVB	Consideration Paid Pursuant To Amalgamation Agreement ConsiderationPaidPursuantToAmalgamationAgreement	39042282	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	486986	usd
CY2021Q3	ENVB	Reserve For Ameri Warrant Liabilities ReserveForAmeriWarrantLiabilities	-262491	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-6510	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2712406	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	55366849	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	22305920	usd
CY2022Q1	ENVB	Stock Issued During Period Value Issued Direct Offering Net One StockIssuedDuringPeriodValueIssuedDirectOfferingNetOne	5802464	usd
CY2022Q1	ENVB	Stock Issued During Period Value Issued Direct Offering Net One StockIssuedDuringPeriodValueIssuedDirectOfferingNetOne	5802464	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	768619	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	88709	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4524014	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	24441698	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	677543	usd
CY2022Q2	ENVB	Issuance Of Redeemable Noncontrolling Series Preferred Stock IssuanceOfRedeemableNoncontrollingSeriesPreferredStock	-527	usd
CY2022Q2	ENVB	Preferred Dividends Attributable To Redeemable Noncontrolling Interest PreferredDividendsAttributableToRedeemableNoncontrollingInterest	-7808	usd
CY2022Q2	ENVB	Accretion Of Embedded Derivative To Redemption Value AccretionOfEmbeddedDerivativeToRedemptionValue	-73994	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-281014	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2790505	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	21965393	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	21965393	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	645137	usd
CY2022Q3	ENVB	Registered Direct Offering Pipe Offering Modification Of Warrants And Exercise Of Prefunded Warrants Net Of Offering Costs RegisteredDirectOfferingPipeOfferingModificationOfWarrantsAndExerciseOfPrefundedWarrantsNetOfOfferingCosts	3249125	usd
CY2022Q3	ENVB	Preferred Dividends Attributable To Redeemable Noncontrolling Interest PreferredDividendsAttributableToRedeemableNoncontrollingInterest	-12603	usd
CY2022Q3	ENVB	Accretion Of Embedded Derivative To Redemption Value AccretionOfEmbeddedDerivativeToRedemptionValue	-110991	usd
CY2022Q3	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue	527	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-417390	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-417390	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2478912	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	22840286	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	22840286	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9793431	usd
	us-gaap	Net Income Loss NetIncomeLoss	-6871406	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3845514	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7077376	usd
	us-gaap	Gain Loss On Investments GainLossOnInvestments	1809622	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-284000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2091299	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	4829484	usd
	ENVB	Inducement Expense InducementExpense	298714	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	103365	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	126563	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	482115	usd
	us-gaap	Depreciation Depreciation	114850	usd
	us-gaap	Depreciation Depreciation	2240	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	758419	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-320123	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-106675	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	625748	usd
	ENVB	Increase Decrease In Right Of Use Lease Liability IncreaseDecreaseInRightOfUseLeaseLiability	91022	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13684606	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7390358	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	577972	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	675000	usd
	ENVB	Proceeds From Amalgamation Agreement ProceedsFromAmalgamationAgreement	3055327	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-577972	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2380327	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	17222100	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21614488	usd
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	958038	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3285164	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18180138	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24899652	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-72554	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-19655	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3845006	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19869966	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	17355999	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1578460	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21201005	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	21448426	usd
	us-gaap	Interest Paid Net InterestPaidNet	5114	usd
	us-gaap	Interest Paid Net InterestPaidNet	5191	usd
	ENVB	Investment Options Issued In Conjunction With Common Stock Issuance InvestmentOptionsIssuedInConjunctionWithCommonStockIssuance	4323734	usd
	ENVB	Modification Of Warrants As Part Of Share Capital Raise ModificationOfWarrantsAsPartOfShareCapitalRaise	251357	usd
	ENVB	Warrants Issued In Conjunction With Notes Payable WarrantsIssuedInConjunctionWithNotesPayable	3595420	usd
	ENVB	Issuance Of Embedded Derivative IssuanceOfEmbeddedDerivative	402000	usd
	ENVB	Preferred Dividends Attributable To Redeemable Noncontrolling Interest PreferredDividendsAttributableToRedeemableNoncontrollingInterest	20411	usd
	ENVB	Accretion Of Embedded Derivative To Redemption Value AccretionOfEmbeddedDerivativeToRedemptionValue	184985	usd
	ENVB	Issuance Of Common Stock Pursuant To Amalgamation IssuanceOfCommonStockPursuantToAmalgamation	39042282	usd
	ENVB	Deferred Tax Liability Incurred Due To Amalgamation DeferredTaxLiabilityIncurredDueToAmalgamation	9061927	usd
	ENVB	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	32754	usd
	ENVB	Fair Value Of Warrants Issued FairValueOfWarrantsIssued	9981000	usd
	ENVB	Fair Value Of Warrants FairValueOfWarrants	262492	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80E_eus-gaap--NatureOfOperations_zR6W7M56mcK5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82E_zihntRvwfJv9">NATURE OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nature of Operations</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Enveric Biosciences, Inc. (“Enveric Biosciences, Inc.” “Enveric” or the “Company”) (formerly known as Ameri Holdings, Inc.) (“Ameri”) is a pharmaceutical company developing innovative, evidence-based cannabinoid medicines. The head office of the Company is located in Naples, Florida. The Company has the following wholly owned subsidiaries: Jay Pharma Inc. (“Jay Pharma”), 1306432 B.C. Ltd. (“HoldCo”), MagicMed Industries, Inc. (“MagicMed”), and Enveric Canada. The Company has an Amalgamation Agreement (“Amalgamation Agreement”) and tender agreement (“Tender Agreement”) with Jay Pharma, which were entered into in prior years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 24, 2021, the Company entered into an Amalgamation Agreement (the “Amalgamation Agreement”) with 1306432 B.C. Ltd., a corporation existing under the laws of the Province of British Columbia and a wholly-owned subsidiary of the Company (“HoldCo”), 1306436 B.C. Ltd., a corporation existing under the laws of the Province of British Columbia and a wholly-owned subsidiary of HoldCo (“Purchaser”), and MagicMed Industries Inc., a corporation existing under the laws of the Province of British Columbia (“MagicMed”), pursuant to which, among other things, the Company, indirectly through Purchaser, acquired all of the outstanding securities of MagicMed in exchange for securities of the Company by way of an amalgamation under the British Columbia Business Corporations Act, upon the terms and conditions set forth in the Amalgamation Agreement, such that, upon completion of the Amalgamation (as defined herein), the amalgamated corporation (“Amalco”) will be an indirect wholly-owned subsidiary of the Company. The Amalgamation was completed on September 16, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MagicMed Industries develops and commercializes psychedelic-derived pharmaceutical candidates. MagicMed’s psychedelic derivatives library, the Psybrary™, is an essential building block from which industry can develop new patented products. The initial focus of the Psybrary™ is on psilocybin and DMT derivatives, and it is then expected to be expanded to other psychedelics.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Akos Spin-Off</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 11, 2022, the Company announced plans to transfer and spin-off its cannabinoid clinical development pipeline assets to Akos Biosciences, Inc. (formerly known as Acanna Therapeutics, Inc.), a majority owned subsidiary of the Company (hereafter referred to as “Akos”), which was incorporated on April 13, 2022, by way of dividend to Enveric shareholders (the “Spin-Off”). The Spin-Off will be subject to various conditions, including Akos meeting the qualifications for listing on the Nasdaq Stock Market, and if successful, would result in two standalone public companies. The new company as a result of the Spin-Off will be referred to as Akos. If the Spin-Off does not occur, the Company has guaranteed the redeemable non-controlling interest (“RNCI”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 5, 2022, the Company and Akos entered into a Securities Purchase Agreement (the “Akos Purchase Agreement”) with an accredited investor (the “Akos Investor”), pursuant to which Akos agreed to sell to the Akos Investor up to an aggregate of <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z3eREUhbgbTg" title="Sale of stock">5,000</span> shares of Akos’ Series A Convertible Preferred Stock (the “Akos Series A Preferred Stock”), par value $<span id="xdx_90A_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z7Tl6Wn3WHRc" title="Preferred stock par value">0.01</span> per share at a price of $<span id="xdx_90F_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zoXoTKi0GjW2" title="Sale of stock price per share">1,000</span> per share, and warrants (the “Akos Warrants”) to purchase shares of Akos’ common stock (the “Akos Common Stock”), par value $<span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember_zZOTelRX55v2" title="Common stock par value">0.01</span> per share, for an aggregate purchase price of up to $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pid_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__srt--RangeAxis__srt--MaximumMember_zGSNPeZH2f9b" title="Sale of stock, value">5,000,000</span> (the “Akos Private Placement”). Pursuant to the Akos Purchase Agreement, Akos has issued <span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z2IshykDKdr9" title="Sale of stock">1,000</span> shares of the Akos Series A Preferred Stock to the Akos Investor in exchange for $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pid_c20220504__20220505__us-gaap--TypeOfArrangementAxis__custom--AkosSecuritiesPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zQY5pAxeorH3" title="Sale of stock, value">1,000,000</span> on May 5, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Reverse Stock Split</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 14, 2022 the Company affected a <span id="xdx_90E_eus-gaap--StockholdersEquityReverseStockSplit_c20220713__20220714_zbtnSRlVdPAa" title="Reverse stock split">1-for-50 reverse stock split.</span> All historical share and per share amounts reflected throughout this report have been adjusted to reflect the Reverse Stock Split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity and Other Uncertainties</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">F<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or the nine months ended September 30, 2022, the Company had a loss from operations of $<span id="xdx_90F_eus-gaap--OperatingIncomeLoss_iN_di_c20220101__20220930_zveUq8K4i7zl" title="Operating income loss">15,159,453</span> and net cash used in operating activities of $<span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_di_c20220101__20220930_zWuYaSwDdV68" title="Net cash used in operating activities">13,684,606</span>. As of September 30, 2022, the Company had an accumulated deficit of $<span id="xdx_909_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_di_c20220930_zDoqAoTgIor3" title="Accumulated deficit">70,529,884</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Since inception, being a research and development company, the Company has not yet generated revenue and the Company has incurred continuing losses from its operations. The Company’s operations have been funded principally through the issuance of debt and equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt/112% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In assessing the Company’s ability to continue as a going concern, the Company monitors and analyzes its cash and its ability to generate sufficient cash flow in the future to support its operating and capital expenditure commitments. At September 30, 2022, the Company had cash of $<span id="xdx_90B_eus-gaap--Cash_iI_c20220930_zzb2zJtP4zO4" title="Cash">21,201,005</span> and working capital of $<span id="xdx_90F_ecustom--WorkingCapital_iI_c20220930_z3obWJFyqUhf" title="Working capital">19,668,572</span>. The Company’s cash on hand at the filing date is estimated to be sufficient to fund operations, however, there can be no guarantee that the conditions will not change and that the Company will require additional funding, which may not be available on acceptable terms or at all, in which case significant delays or cost increases may result in material disruption to the Company’s operations. In such case, the Company would be required to delay, scale back or eliminate some or all of its research and development programs, which would likely have a material adverse effect on the Company and its financial statements.</p> <p style="font: 10pt/112% Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s material cash requirements consist of working capital to fund capital expenditures incurred at their research facility in Calgary and their operations, which consist primarily of, without limitation, employee related expenses, product development activities conducted by third parties, research materials and lab supplies, facility related expenses including rent and maintenance, costs associated with preclinical studies, patent related costs, costs of regulatory and public company compliance, insurance costs, audit costs, consultants and legal fees. Additionally, the Company currently utilizes third-party contract CROs to assist with clinical development activities. If the Company obtains regulatory approval for any of their product candidates, they expect to incur significant expenses to engage third-party contract CMOs to carry out their clinical manufacturing activities as they do not yet have a commercial organization, and incur significant expenses related to developing their internal commercialization capability to support product sales, marketing and distribution. The Company’s current working capital resources are sufficient to fund these material cash requirements for the next twelve months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expects to finance future cash needs through public or private equity offerings, debt financings, or business development transactions. If adequate funds are not available, the Company may be required to delay, reduce the scope of or eliminate research and development programs or obtain funds through arrangements with collaborators or others that may require the Company to relinquish rights to certain pipeline candidates that they might otherwise seek to develop or commercialize independently.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq Notice</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 18, 2022, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between January 5, 2022, through February 17, 2022, the Company did not meet the minimum bid price of $<span id="xdx_905_eus-gaap--SharePrice_iI_c20220218__srt--RangeAxis__srt--MinimumMember_zjhBYkPk0H0d" title="Share price">1.00</span> per share required for continued listing on the Nasdaq Capital Market (“Nasdaq”) pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until August 17, 2022 (the “Compliance Period”), in which to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 29, 2022, the Company received a letter from the Listing Qualifications Department of the Nasdaq Stock Market stating that for the last ten consecutive business days, from July 15 to July 28, 2022, the closing bid price of the Company’s common stock had been at $<span id="xdx_900_eus-gaap--SharePrice_iI_c20220719__srt--RangeAxis__srt--MinimumMember_zmkawMb2fXf7" title="Share price">1.00</span> per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-50 reverse stock split.
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15159453	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13684606	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70529884	usd
CY2022Q3	us-gaap	Cash Cash	21201005	usd
CY2022Q3	ENVB	Working Capital WorkingCapital	19668572	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84D_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zFOQynnTpmc9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_ztKisk4fYzz6">Reclassification</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain reclassifications have been made to the prior period financial statements to conform to the current period financial statement presentation. Certain amounts related to depreciation and amortization from the prior period were reclassified from General and administrative line item to Depreciation and amortization line item on the Unaudited Condensed Consolidated Statement of Operations and Comprehensive Income (Loss). These reclassifications had no net effect on loss from operations, net loss, or cash flows as previously reported.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ENVERIC BIOSCIENCES, INC. AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_znqFI6gZLWAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zlyl4ip9TwAk">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and expenses during the periods reported. By their nature, these estimates are subject to measurement uncertainty and the effects on the financial statements of changes in such estimates in future periods could be significant. Significant areas requiring management’s estimates and assumptions include determining the fair value of transactions involving common stock and the valuation of stock-based compensation, accruals associated with third party providers supporting research and development efforts, estimated fair values of long lives assets used to record impairment charges related to intangible assets, acquired in-process research and development (“IPR&D”), and goodwill, and allocation of purchase price in business acquisitions. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Stock Issued1 StockIssued1	767500	usd
	us-gaap	Stock Issued1 StockIssued1	767500	usd
CY2022Q3	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.0001
	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.0001
CY2022Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1875811	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1875811	shares
CY2021Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	350563	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	350563	shares
CY2021Q4	us-gaap	Goodwill Goodwill	1587634	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-119245	usd
CY2022Q3	us-gaap	Goodwill Goodwill	1468389	usd
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	6375492	usd
	us-gaap	Indefinite Lived Intangible Assets Foreign Currency Translation Gain Loss IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss	-478856	usd
CY2022Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	5896636	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	548436	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	126563	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	421873	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	42187	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	170692	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	126563	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	482115	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M18D
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	42187	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	168750	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	168750	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	42186	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	421873	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	131885	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	27345	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	712944	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	294430	usd
CY2022Q3	us-gaap	Depreciation Depreciation	44458	usd
CY2021Q3	us-gaap	Depreciation Depreciation	2240	usd
	us-gaap	Depreciation Depreciation	114850	usd
	us-gaap	Depreciation Depreciation	2240	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q3	us-gaap	Share Price SharePrice	0.0001
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	(i) increase the aggregate number of shares available for the grant of awards by 146,083 shares to a total of 200,000 shares, and (ii) add an “evergreen” provision whereby the number of shares authorized for issuance pursuant to awards under the Incentive Plan will be automatically increased on the first trading date immediately following the date the Company issues any share of Common Stock (defined below) to any person or entity, to the extent necessary so that the number of shares of the Company’s Common Stock authorized for issuance under the Incentive Plan will equal the greater of (x) 200,000 shares, and (y) 15% of the total number of shares of the Company’s Common Stock outstanding as of such issuance date. The Plan Amendment was approved by the Company’s stockholders at a special meeting of the Company’s stockholders held on July 14, 2022.
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	23829	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	79.00
CY2021Q4	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	103.50
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	34333	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	175.00
	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Expired Forfeited Or Cancelled Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrCancelledWeightedAverageGrantDateFairValue	140.50
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	22829	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	75.00
CY2022Q3	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	101.50
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y3M18D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	19690	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	74.93
CY2022Q3	ENVB	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	101.00
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y9M18D
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	590190	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	434403	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1932553	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4711222	usd
	ENVB	Redeemable Noncontrolling Interest Embedded Derivative RedeemableNoncontrollingInterestEmbeddedDerivative	402000	usd
	ENVB	Redeemable Noncontrolling Interest Issuance Costs RedeemableNoncontrollingInterestIssuanceCosts	41962	usd
	ENVB	Redeemable Noncontrolling Interest Embedded Derivative And Net Of Issuance Costs Shares RedeemableNoncontrollingInterestEmbeddedDerivativeAndNetOfIssuanceCostsShares	556038	shares
	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	20411	usd
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	184985	usd
CY2022Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	761434	usd
	ENVB	License Agreement Description LicenseAgreementDescription	Jay Pharma, Tikkun Olam LLC (“TO LLC”) and Tikkun Olam Hemp LLC (“TOH”) entered into a license agreement dated on January 10, 2020, pursuant to which Jay Pharma would acquire certain in-licensed and owned intellectual property rights related to the cannabis products in the United States (presently excluding the state of New York) from TO LLC and TOH, each of which is an affiliate of TO Holdings Group LLC, in exchange for royalty payments of (i) four percent (4.0%) of net sales of OTC cancer products made via consumer channels; and (ii) five percent (5.0%) of net sales of beauty products made via consumer channels; and (iii) three percent (3.0%) of net sales of OTC cancer products made via professional channels, along with a minimum net royalty payment starting in January 1, 2022 and progressively increasing up to a cap of $400,000 maximum each year for the first 10 years, then $600,000 maximum each year for the next 5 years, and an annual maximum cap of $750,000 each year thereafter during the term of the agreement
CY2021Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	9061927	usd
CY2021	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	1607122	usd
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	29048164	usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	8225862	usd
CY2022Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1486413	usd

Files In Submission

Name	View Source	Status
0001493152-22-032131-index-headers.html	Edgar Link	pending
0001493152-22-032131-index.html	Edgar Link	pending
0001493152-22-032131.txt	Edgar Link	pending
0001493152-22-032131-xbrl.zip	Edgar Link	pending
envb-20220930.xsd	Edgar Link	pending
ex-32.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
envb-20220930_cal.xml	Edgar Link	unprocessable
envb-20220930_def.xml	Edgar Link	unprocessable
envb-20220930_lab.xml	Edgar Link	unprocessable
envb-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENVB
Enveric Biosciences, Inc. Stock $envb

2022 Q4 Form 10-Q Financial Statement

#000149315222032131 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENVB Enveric Biosciences, Inc. Stock $envb

2022 Q4 Form 10-Q Financial Statement

#000149315222032131 Filed on November 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENVB
Enveric Biosciences, Inc. Stock $envb